Chin, Jungwook Hong, Jun Young Lee, Jaehwan Hwang, Hoosang Ko, Hyunsil Choi, Hyukjae Hahn, Dongyup Ko, Jaeyoung Nam, Sang-Jip Tak, Jungae Ham, Jungyeob Kang, Heonjoong 2024-01-20T18:02:25Z 2024-01-20T18:02:25Z 2021-09-05 2010-12-15 0960-894X https://pubs.kist.re.kr/handle/201004/130824 We report the synthesis and in vivo activity of a novel anti-atherogenic agent, isosteric selenium PPAR delta-selective ligand. This ligand did not cause significant body or liver weight changes and did not have obvious adverse effects on intestinal polyp formation. Our overall results clearly demonstrate that PPAR delta is a viable drug candidate for targeting and treating atherosclerosis. (C) 2010 Elsevier Ltd. All rights reserved. English Pergamon Press Ltd. PPAR-DELTA MOLECULAR MODIFICATION ATHEROSCLEROSIS CHOLESTEROL SULFIDES BIOISOSTERISM BETA/DELTA MODELS HEART MICE Selective peroxisome proliferator-activated receptor delta isosteric selenium agonists as potent anti-atherogenic agents in vivo Article 10.1016/j.bmcl.2010.10.103 1 Bioorganic & Medicinal Chemistry Letters, v.20, no.24, pp.7239 - 7242 Bioorganic & Medicinal Chemistry Letters 20 24 7239 7242 scie scopus 000284332900010 2-s2.0-78449273353 Chemistry, Medicinal Chemistry, Organic Pharmacology & Pharmacy Chemistry Article PPAR-DELTA MOLECULAR MODIFICATION ATHEROSCLEROSIS CHOLESTEROL SULFIDES BIOISOSTERISM BETA/DELTA MODELS HEART MICE PPAR delta-selective ligand Anti-atherogenic agents Intestinal polyp formation